Early Caffeine administration

Phase 3Small molecule

HHospital de Clinicas de Porto Alegre

Early Caffeine administration is one of 8 small molecule programs targeting Neonatal. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeonatalRecruiting

NeonatalPhase 3

Recruiting

Competition

Competitive Landscape

9 competitors in Neonatal

#DrugCompanyPhaseTrials

Fabhalta

Johnson & Johnson

Phase 3

2 2

Rayos

RRoxane Laboratories

Phase 3

1 3

Ivig

Argenx

Phase 3

1 4

Immunoglobulins

CSL Behring

Phase 3

1 5

Pitressin

AAultman Health Foundation

Phase 1

1 6

Pulmicort

SSalix

Phase 1

1 7

Early Caffeine administration

HHospital de Clinicas de Porto Alegre

Phase 3

1 8

Colostrum

HHadassah Medical Organization

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neonatal1 trial

The Caffeine Therapy in the Fetal to Neonatal Transition

Recruiting·HHospital de Clinicas de Porto Alegre·Phase 4·NCT05454332·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Early Caffeine administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Early Caffeine administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Early Caffeine administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital de Clinicas de Porto Alegre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospital de Clinicas de Porto Alegre

Early Caffeine administration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neonatal1 trial

References

Drug Info

Quick Facts

Related News